Scotiabank raised the firm’s price target on Twist Bioscience to $50 from $48 and keeps an Outperform rating on the shares. The firm’s Q3 revenues and gross margin beat expectations and guidance, the analyst tells investors. Further, the firm believes the company is sufficiently capitalized to take SynBio and next-generation sequencing to profitability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Twist Bioscience and bitBiome collaborate on enzymes for biocatalysis
- Twist Bioscience price target raised to $46 from $40 at Baird
- Twist Bioscience price target lowered to $55 from $60 at Barclays
- TWST Earnings this Week: How Will it Perform?
- Twist Bioscience says first patient dosed in Pure Biologics’ BA-0405 study